Remedy Robotics, Mission Thrombectomy extend N1 System to blood clot removal

Remedy Robotics Inc. this week said it is working with Mission Thrombectomy to expand access to blood clot removal in the U.S. and worldwide using Remedy’s N1 System. Through this partnership, Remedy will become Mission Thrombectomy’s exclusive robotics partner.

As part of the strategic agreement, Remedy Robotics will closely collaborate with Mission Thrombectomy’s clinical network to test, develop, and guide the global rollout of its telerobotic technology into stroke-thrombectomy workflows. This network includes regional committees in over 100 countries, and the broader Society of Vascular and Interventional Neurology (SVIN) network.

“We are thrilled that Mission Thrombectomy has selected Remedy Robotics as its exclusive robotics partner to expand access to endovascular thrombectomy for stroke patients both in the U.S. and worldwide,” said Dr. David Bell, co-founder and CEO of Remedy Robotics.

“This collaboration will advance our shared vision of making the best endovascular intervention available to patients, wherever they are,” he added. “Working with Mission Thrombectomy’s world-class clinicians and global network, we will make endovascular thrombectomy safer and more equitably accessible to patients across the U.S. and the world.”

Remedy Robotics to accelerate N1 deployment

The partnership builds on Mission Thrombectomy’s work in research, clinician training, guideline development, and global advocacy for endovascular thrombectomy. Together, the two organizations said they will work to accelerate the deployment of Remedy’s N1 System to expand access to thrombectomy in the U.S. and globally, particularly in underserved regions.

The company released its N1 System, a remotely operated endovascular robot, earlier this year. The system combines proprietary hardware and AI-enabled software to enable faster, safer, and more effective treatment of cardiovascular conditions. Those include stroke, heart attack, or vascular trauma, whether across the room or across the globe.

Remedy Robotics raised $35 million and completed its first fully remote procedures in Toronto earlier this month. It also partnered with the Australian Stroke Alliance to expand remote care. The San Francisco-based company’s competitors in the endovascular robotics space include Microbot Medical and Stereotaxis.

Thrombectomy access is limited in the U.S. and abroad

Endovascular thrombectomy for acute ischemic stroke, a procedure involving the removal of a clot from a vessel in the brain, is the most effective treatment for the most severe strokes, Remedy Robotics said. This treatment is complex and extremely time-sensitive: Patients treated promptly can walk home, while those treated after delays face permanent brain damage and disability.

The recent MT-GLASS study by Mission Thrombectomy found that only one-third of Americans have access to endovascular thrombectomy without delay. This vastly outstrips availability in low-income countries, where the mean access rate is less than 1%.

“No patient’s chance of recovery should depend on their ZIP code. At Mission Thrombectomy, our goal is to ensure that the life-saving benefits of endovascular thrombectomy are available to patients worldwide without delay,” said Fawaz Al-Mufti, M.D., global chair of Mission Thrombectomy. “By combining our clinical network, training programs, and global advocacy reach with Remedy’s groundbreaking telerobotic technology, we can dramatically expand access to this life-saving treatment.”

Less than 3% of the global population has access to this care, according to Remedy Robotics. These figures underscore the urgent need for a scalable, reliable solution to make safe and effective thrombectomy available to patients everywhere, it said.

“Access to thrombectomy is dismally low globally, despite it being a brain-saving, disability-sparing, and life-saving therapy,” noted Dileep Yavagal, M.D., founder and global chair-emeritus of Mission Thrombectomy. “More than 97% of patients are being left untreated.”

“Remedy Robotics’ technology offers a powerful new avenue to solve this challenge by allowing clinicians to provide the best care remotely to patients immediately, wherever they are in the world,” he said. “We are excited that Remedy has chosen to partner with Mission Thrombectomy and to work with them as we continue to champion national and worldwide access to thrombectomy.”